艾塞那肽微球对2型糖尿病患者胰岛素抵抗及炎症因子的影响

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (858 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effects of Exenatide Microspheres on insulin resistance and inflammatory factors in patients with type 2 diabetes. Methods A total of 90 patients with type 2 diabetes treated in the Department of Endocrinology of the Second Hospital of Jilin University from September 2018 to June 2019 were collected. According to the random number table method, the patients were randomly divided into the control group (Metformin Hydrochloride) and the observation group (Exenatide Microspheres), with 45 cases in each group, treated for 24 weeks. The levels of clinical biochemical indexes and inflammation markers were compared between the two groups before and after treatment. Results A total of 10 cases withdrew from the study due to side effects or loss of follow-up, and 80 cases entered the statistical analysis, with 40 cases each. After 24 weeks of treatment, the weight, body mass index (BMI), fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin, triglycerides, total cholesterol (TC), low density lipoprotein-cholesterol, fasting insulin (FINS), homeostasis model assessment of insulin resistance index (HOMA-IR), interleukin-6, tumor necrosis factor-α (TNF-α) and high mobility group box-1 protein (HMGB1) levels of the two groups were lower than those before treatment, and the differences were statistically significant (P ＜ 0.05), and there was no significant difference in the high density lipoprotein-cholesterol (HDL-C) level compared with that before treatment (P ＞ 0.05). After treatment, the FINS, HOMA-IR, TNF-α and HMGB1 levels of the observation group were lower than those of the control group, the differences were statistically significant (P ＜ 0.05). Conclusion The Exenatide Microspheres can improve islet function of patients with type 2 diabetes, which may be related to the anti-inflammatory effect of Exenatide Microspheres.

Key words： Exenatide Microspheres Diabetes Insulin resistance High mobility group box-1 protein Anti-inflammatory

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIAN Mingzhu ZHAO Ying KANG Jing CHEN Yan

Cite this article:

LIAN Mingzhu ZHAO Ying KANG Jing CHEN Yan. Effects of Exenatide Microspheres on insulin resistance and inflammatory factors in patients with type 2 diabetes[J]. 中国医药导报, 2020, 17(24): 67-70,83.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I24/67

[1] Stumvoll M，Goldstein BJ，van Haeften TW. Type 2 diabetes： principles of pathogenesis and therapy [J]. Lancet，2005，365（9467）：1333-1346.
[2] 陈立立，胡仁明.2型糖尿病发病的炎症机制[J].中华糖尿病杂志，2012，4（4）：248-251.
[3] Davies MJ，D'Alessio DA，Fradkin J，et al. Management of Hyperglycemia in Type 2 Diabetes，2018. A Consensus Report by the American Diabetes Association （ADA） and the European Association for the Study of Diabetes（EASD） [J]. Diabetes Care，2018，41（12）：2669-2701.
[4] Tomita T. Apoptosis in pancreatic β-islet cells in Type 2 diabetes [J]. Bosn Basic Med Sci，2016，16（3）：162-179.
[5] Schofield CJ，Sutherland C. Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes [J]. Diabet Med，2012，29（8）：972-979.
[6] 洪天配，母义明，纪立农，等.2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识[J].中国糖尿病杂志，2017，25（6）：481-492.
[7] 杨超，胡莹茹，熊家瑶，等.GLP-1受体激动剂对2型糖尿病心血管的益处及机制研究进展[J].现代医药卫生，2019，35（4）：550-553.
[8] Garber AJ，Abrahamson MJ，Barzilay JI，et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2017 Executive Summary [J]. Endocr Pract，2017，23（2）：207-238.
[9] Kapodistria K，Tsilibary EP，Kotsopoulou E，et al. Liraglutide，a human glucagon-like peptide-1 analogue，stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis [J]. Cell Mol Med，2018，22（6）：2970-2980.
[10] 刘晓妮，王颖，李桃桃，等.2型糖尿病合并代谢综合征患者胰岛素抵抗指数与慢性炎症指标相关性研究[J].检验医学，2019，34（9）：826-830.
[11] Wang Y，Zhong J，Zhang X，et al. The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes [J]. Exp Diabetes Res, 2016，2016：2543268.
[12] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J]中华糖尿病杂志，2018，10（1）：4-67.
[13] Fizelova M，Jauhiainen R，Kangas AJ，et al. Differential Associations of Inflammatory Markers With Insulin Sensitivity and Secretion：The Prospective METSIM Study [J]. Clin Endocrinol Metab，2017，102（9）：3600-3609.
[14] Aroda VR. A review of GLP-1 receptor agonists：Evolution and advancement，through the lens of randomised controlled trials [J]. Diabetes Obes Metab，2018，20（Suppl 1）：22-33.
[15] 纪立农，邹大进，洪天配，等.GLP-1受体激动剂临床应用专家指导意见[J].中国糖尿病杂志，2018，26（5）：353-361.
[16] 王米娜，金安林，高欣彤.艾塞那肽对老年腹型肥胖2型糖尿病患者胰岛α、β细胞功能及血清FGF-21、CTRP3水平的影响[J].海南医学，2019，30（17）：2200-2202.
[17] Retnakaran R，Kramer CK，Zinman B，et al. Response to Comment on Retnakaran et al. Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 2014；37：3270-3278 [J]. Diabetes Care，2015，38（2）：e26.
[18] Pratley RE，Nauck M，Bailey T，et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin：a 26-week，randomised，parallel-group，open-label trial [J]. The Lancet，2010，375（9724）：1447-1456.
[19] 朱祎婧，胡朝恩，钟大鹏，等.艾塞那肽通过TLR-3信号减轻糖脂毒性对胰岛β细胞的损害[J].西南国防医药，2019，29（8）：823-826.
[20] 中华医学会糖尿病学分会胰岛素抵抗学组（筹）.胰岛素抵抗评估方法和应用的专家指导意见[J].中华糖尿病杂志，2018，10（6）：377-385.
[21] Eguchi K，Nagai R. Islet inflammation in type 2 diabetes and physiology [J]. Clin Invest，2017，127（1）：14-23.
[22] Pahwa R，Jialal I. The role of the high-mobility group box1 protein-Toll like receptor pathway in diabetic vascular disease [J]. Diabetes Complications，2016，30（6）：1186-1191.
[23] Lee YS，Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells [J]. Metabolism，2014， 63（1）：9-19.
[24] 姚欢欢，陈吉，陈思思，等.基于AMPK/GLUT4/GSK3β/PPARα信号通路研究地骨皮水提物改善2型糖尿病大鼠胰岛素抵抗的实验研究[J].中国医药导报，2020， 17（5）：8-12，198.
[25] 李居一，张媛媛，倪英群，等.利拉鲁肽对2型糖尿病患者胰岛功能、炎症状态及心血管危险因素的影响[J].湖南师范大学学报：医学版，2019，16（5）：190-192.
[26] Guo C，Huang T，Chen A，et al. Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages [J]. Braz J Med Biol Res，2016， 49（12）：e5826.